



Press release
Gothenburg, Sweden
July 14, 2020. 10:00 CET

CELLINK and Kugelmeiers Ltd. announce strategic partnership for 3D printing cell spheroids

Today, CELLINK announced a distribution partnership with Kugelmeiers Ltd. to bring to market CELLINK Spheroid Kits, which package Kugelmeiers Sphericalplate 5D for forming highly standardized spheroids with CELLINK's vast portfolio of bioinks. The Spheroid Kits will be distributed globally, except in Japan and Switzerland, through CELLINK's existing marketing and distribution network.

Culturing cell spheroids is an important emerging field for cell biologists that can be used in scientific, diagnostic and therapeutic applications. When coupled with 3D bioprinting, the enhanced biological functionality and accuracy of spheroids can be used like “building blocks” for tissue engineering. Kugelmeiers and CELLINK are proud of this partnership that makes CELLINK Spheroid Kits available to help researchers optimize workflows for an automated solution to spheroid development.

CELLINK recognizes the paradigm shift toward 3D cellular models in medical research and is committed to providing scientists with better access to the necessary tools and supplies. As demonstrated in the literature, 3D models better mimic in vivo conditions, and CELLINK researchers have found that pairing CELLINK's bioinks with Kugelmeiers' Sphericalplate 5D results in improved cellular rearrangement and yields more physiologically relevant data about cellular behavior. A recent CELLINK [white paper](#) outlines the benefits of spheroids within the realm of 3D cell culture.

Magnus Lindeberg, Bioprinting Product Manager, CELLINK:

“We are happy to partner with Kugelmeiers on this distribution agreement for the cutting-edge Sphericalplate 5D, which complements our existing portfolio of 3D cell culturing technologies and expanding library of high-quality bioinks. CELLINK strongly believes 3D cell culturing is the future of medicine and is committed to researching, developing and distributing to the scientific community the tools vital to making that change a reality.”

Manfred Vogel, Director of Sales, Kugelmeiers:

“In Kugelmeiers vision to enable unlimited cell therapies, it is a great honour for us to partner with CELLINK - the leading provider for 3D bioprinting technologies. We strongly believe that the combination of the high quality bioinks from CELLINK and our 3D cell culture technology Sphericalplate 5D will help to find functional and empowering solutions for the global scientific, diagnostic and medical community. ”

For more information on the CELLINK Spheroid Kit, visit www.cellink.com/spheroid-kit/.

For further information, please contact:

Erik Gatenholm, CEO

Phone (Sweden): +46 73 267 00 00

Phone (US): +1 (650) 515 5566

Email: eg@cellink.com

Gusten Danielsson, CFO

Phone (Sweden): +46 70 991 86 04

Phone (US): +1 (857) 332 2138

Email: gd@cellink.com

About CELLINK

CELLINK is a life-science company developing and delivering life-science solutions for cell culturing, with a focus on three application areas, bioprinting, analysis, and liquid handling and bioprocessing. It develops and markets cell culture technologies, enabling researchers in the life sciences to print human organs and tissues for pharmaceutical and cosmetic applications.

Founded in 2016 with a global reach in more than 55 countries, CELLINK is changing the future of medicine as we know it.

Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.

About Kugelmeiers

Kugelmeiers Ltd., based in Erlenbach, Zurich, Switzerland, was founded in 2015 as a spin-off of the University of Zurich. The company evolved from the clinical human islet transplantation program of the University Hospital Zurich for the Treatment of Diabetes. The clinical need for functional pancreatic tissue was the driver for 10 years of research and development to create a platform for future cell transplantation applications. The first laboratory platform, the Sphericalplate 5D allows various scientific applications by standardizing the mass production of spheroids. Kugelmeiers is also actively involved in the development of promising future cell therapies. The company incorporates science, surgery, transplantation networks and entrepreneurship.

For more information, visit www.kugelmeiers.com.